Momelotinib, also known as CYT387, is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 = 0.16 μM). As of 2011, CYT387 is being developed as a drug for myelofibrosis and currently undergoes Phase I/II clinical trials. Additional potential treatment indications for CYT387 include other myeloproliferative neoplasms, cancer (solid and liquid tumors) and inflammatory conditions.
JAK Inhibitors Related Products:
Ruxolitinib; Ruxolitinib phosphate; Tofacitinib; AZD1480; Gandotinib; AZ960; Pacritinib; XL019; Upadacitinib; Decernotinib; Filgotinib; GLPG0634 analogue; FLLL32; AG-490 (Tyrphostin B42); NSC-42834; Itacitinib; Go6976; Baricitinib; Oclacitinib; Oclacitinib maleate; WP1066